219917-38-1

Basic information

• Product Name: 2-(1,3-benzothiazol-2-ylsulfanyl)-1-(3,4-dihydroxyphenyl)ethanone
• Synonyms: 2-(1,3-benzothiazol-2-ylsulfanyl)-1-(3,4-dihydroxyphenyl)ethanone
• CAS NO: 219917-38-1
• Molecular Formula: C15H11NO3S2
• Molecular Weight: 317.38274
• Mol File: 219917-38-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(1,3-benzothiazol-2-ylsulfanyl)-1-(3,4-dihydroxyphenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1,3-benzothiazol-2-ylsulfanyl)-1-(3,4-dihydroxyphenyl)ethanone(219917-38-1)
• EPA Substance Registry System: 2-(1,3-benzothiazol-2-ylsulfanyl)-1-(3,4-dihydroxyphenyl)ethanone(219917-38-1)

Safety Data

• Hazardous Substances Data: 219917-38-1(Hazardous Substances Data)

Upstream product

• 99-40-1 2-chloro-3',4'-dihydroxyacetophenone 
• 149-30-4 2-Mercaptobenzothiazole 
• 6860-95-3 1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)ethanone 
• 1380732-96-6 2-(benzo[d]thiazol-2-ylthio)-1-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)ethanone 
• 1197-09-7 1-(3,4-dihydroxyphenyl)ethan-1-one 
• 120-80-9 benzene-1,2-diol 

Relevant articles and documents

Elucidation of Mycobacterium tuberculosis TypeII Dehydroquinase Inhibitors using a Fragment Elaboration Strategy

A library of novel Mycobacterium tuberculosis typeII dehydroquinase (DHQase) inhibitors were discovered through the use of a fragment elaboration approach. Putative active site binding fragments were initially assessed insilico which led to the selection of two small aromatic fragments for further investigation. Synthetic elaboration of the fragments provided a library of 34 inhibitors that exhibited low-micromolar inhibition of typeII DHQase. A number of these inhibitors also showed antibacterial activity in the low-micromolar range in screens against M. tuberculosis invitro; these now serve as lead compounds for further development of therapeutics for the treatment of tuberculosis.

Discovery and structure-activity relationship of the first non-pep tide competitive human glucagon receptor antagonists

The first non-peptide competitive human glucagon receptor antagonist, 2-(benzimidazol-2ylthio)-l-(3,4-dihydroxyphenyl)-l-ethanone, NNC 92-1687 (2), is described. This antagonist has a binding affinity of 20 μM (ICso) and a functional Ki = 9.1 μM at the human glucagon receptor. A structure-activity relationship (SAR) was obtained on this compound, and the results show that only the benzimidazole part can be changed without complete loss of affinity. Analogues with tert-butyl or benzyloxy groups in the 5-position of the benzimidazole moiety were found to be equipotent or slightly more potent, all displaying binding affinities around 5-20 μM. Most of the changes to the catechol and the linker gave compounds without any affinity toward the human glucagon receptor. The 3-hydroxy group could, however, in the presence of a 4-hydroxy group be changed to a methoxy or a chloro group while retaining affinity.